乳腺多形性小叶癌：4例曲妥珠单抗长期反应者——巧合还是提示？ - Suppr

Suppr

超能文献

Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?

作者信息

Mahtani Reshma L, Vogel Charles L

出版信息

J Clin Oncol. 2008 Dec 10;26(35):5823-4. doi: 10.1200/JCO.2008.19.8226. Epub 2008 Nov 10.

DOI:10.1200/JCO.2008.19.8226

PMID:19001341

Abstract

摘要

相似文献

Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?乳腺多形性小叶癌：4例曲妥珠单抗长期反应者——巧合还是提示？

J Clin Oncol. 2008 Dec 10;26(35):5823-4. doi: 10.1200/JCO.2008.19.8226. Epub 2008 Nov 10.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.赫赛汀（曲妥珠单抗）：辅助治疗和新辅助治疗试验。

Isr Med Assoc J. 2006 Jun;8(6):416-21.

Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.HER-2检测的最新趋势以及针对原发性和转移性乳腺癌的曲妥珠单抗治疗新策略。

Breast Cancer. 2009;16(4):283. doi: 10.1007/s12282-009-0168-y.

Trastuzumab in breast cancer.曲妥珠单抗在乳腺癌中的应用

N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4.

Isolated tumor cells in breast cancer.乳腺癌中的孤立肿瘤细胞。

N Engl J Med. 2009 Nov 12;361(20):1995; author reply 1995-6.

Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.早期HER2阳性乳腺癌初次治疗后使用曲妥珠单抗可降低复发率。

Cancer Treat Rev. 2006 Apr;32(2):144-8. doi: 10.1016/j.ctrv.2006.01.005. Epub 2006 Mar 6.

[Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].曲妥珠单抗（赫赛汀）用于HER-2阳性早期乳腺癌的辅助治疗

Magy Onkol. 2006;50(4):293-302. Epub 2007 Jan 10.

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.优化人表皮生长因子受体2阳性乳腺癌的治疗：T代表曲妥珠单抗、肿瘤大小和治疗策略。

J Clin Oncol. 2009 Dec 1;27(34):5671-3. doi: 10.1200/JCO.2009.24.2222. Epub 2009 Nov 2.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.新辅助化疗加曲妥珠单抗治疗后病理完全缓解可预测人表皮生长因子受体 2 过表达乳腺癌的良好生存：AGO 和 GBG 研究组的 TECHNO 试验结果。

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.肿瘤细胞中 Foxp3 表达的存在预示着接受新辅助化疗的 HER2 过表达乳腺癌患者的生存更好。

Breast Cancer Res Treat. 2011 Jan;125(1):65-72. doi: 10.1007/s10549-010-0831-1. Epub 2010 Mar 13.

引用本文的文献

Pleomorphic Carcinoma of the Breast: A Report of Three Cases.乳腺多形性癌：三例报告

Cureus. 2024 May 26;16(5):e61091. doi: 10.7759/cureus.61091. eCollection 2024 May.

Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.三阴性或 HER2 阳性乳腺癌患者的临床结局：单中心经验。

Breast Cancer Res Treat. 2022 Apr;192(3):563-571. doi: 10.1007/s10549-021-06432-z. Epub 2022 Feb 4.

Rare epithelial breast cancer: surgery and adjuvant therapy.罕见上皮性乳腺癌：手术及辅助治疗

Transl Cancer Res. 2019 Oct;8(Suppl 5):S479-S492. doi: 10.21037/tcr.2019.05.12.

Rare Breast Cancer Subtypes.罕见乳腺癌亚型。

Curr Oncol Rep. 2021 Mar 23;23(5):54. doi: 10.1007/s11912-021-01048-4.

Case of HER2neu+ Invasive Pleomorphic Lobular Carcinoma With Response to Conventional Neoadjuvant Chemotherapy: A Viable Option for an Exceedingly Rare Breast Cancer Type.HER2neu+侵袭性多形性小叶癌对传统新辅助化疗有反应的病例：一种极其罕见的乳腺癌类型的可行选择。

Cureus. 2020 Oct 23;12(10):e11108. doi: 10.7759/cureus.11108.

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.致癌作用的进化动力学及靶向治疗为何无效。

Nat Rev Cancer. 2012 Jun 14;12(7):487-93. doi: 10.1038/nrc3298.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验